Shumeile generic drugs into the clinical phase III AbbVie pressure mountain

On October 8, 2015, a successful drug could generate billions of dollars in revenue for biopharmaceutical companies. However, if the best-selling drug is about to lose patent protection, then the smell of generic drug research and development will make the company's money tree instantly disappear.
with the advent of the "patent cliff" of biopharmaceuticals, more and more biopharmaceutical companies have a personal feeling about this. AbbVie, which holds humira, the world's best-selling drug, has a deep understanding of this.
recently, researchers from Baxalta and Momta Biopharmaceuticals announced that M923, a generic drug product developed jointly by the two companies, was entering clinical phase III. The news certainly darkens Humira's prospects after losing patent protection. Baxalta and Momenta have been allied with Humira since 2011. The researchers plan to conduct a clinical Phase III study of M923's treatment of chronic plaque-type psoriasis. If all goes well, the two companies plan to submit applications for the drug in 2017.
, the predecessor of Baxalta, in 2011 teamed up with Momenta to develop Humira generics. Baxter paid $33 million in advances and up to $419 million in milestone bonuses. But they aren't the only ones eyeing Humira as a money-slinging tree. This summer, Mercedon and Samsung Bioepis have pushed their Humira generic versions into clinical phase III. In addition, Novarma and Amjin are ready to split humira's market share.
was undoubtedly the most painful time for Humira's owner, AbbVie. Humira's patent protection period is about to expire in 2015, which means that the cash-for-money tree that has brought the company tens of billions of dollars a year in the past is no longer enough. In 2014 alone, Humira brought in $12.5 billion for AbbVie, according to the data, more than even the total sales of many pharmaceutical companies.
but as one of the oldest pharmaceutical giants, it's clear that AbbVie won't sit back and wait. In recent years, AbbVie has made a number of acquisitions of promising drug projects to make up for Humira's loss. Earlier this year, AbbVie paid $21 billion for Pharmacyclics and acquired 50 percent ownership of Imbruvica, a leukemia drug it developed with Johnson and Johnson. In addition, vikiraPak, the company's hepatitis C drug, which went on sale in 2014, is considered one of the potential challengers to Gilead, the dominant company in the field. (Bio Valley)